New 3-Drug cocktail targets Hard-to-Treat leukemia
NCT ID NCT03874052
First seen Apr 25, 2026 · Last updated May 03, 2026 · Updated 2 times
Summary
This early-phase study tests whether adding ruxolitinib to two standard drugs (azacitidine and venetoclax) is safe and tolerable for people with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. About 51 adults will receive the combination to find the best dose and see if it helps control the cancer. The goal is disease control, not a cure, as ongoing treatment is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ohio State University Comprehensive Cancer Center
SUSPENDEDColumbus, Ohio, 43210, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
SUSPENDEDDallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.